Hims & Hers Stock Surges on Reported Novo Nordisk Partnership, But Regulatory Overhang Remains

What happened

Hims & Hers shares spiked nearly 50% in premarket trading after a report indicated the company ended its dispute with Novo Nordisk by forming a partnership, potentially alleviating a key litigation risk highlighted in the DeepValue report. The DeepValue master report had flagged Novo Nordisk's patent-infringement lawsuit and FDA actions as critical threats to HIMS's compounded semaglutide business, which underpins its FY2026 guidance. However, this partnership does not directly address the FDA's explicit intent to restrict GLP-1 APIs for mass-marketed compounded drugs, a regulatory risk that remains unresolved. Investors are reacting to reduced legal uncertainty, but the company's guidance still assumes ongoing access to compounded semaglutide, leaving it vulnerable to enforcement shifts. Thus, while the stock move reflects relief on one front, the broader investment thesis must now weigh litigation respite against persistent regulatory headwinds.

Implication

The reported partnership with Novo Nordisk reduces the near-term litigation overhang, but investors must still price in high regulatory uncertainty from FDA actions targeting compounded semaglutide access. HIMS's valuation at 29x P/E and 26x EV/EBITDA remains stretched given the guidance dependency on this contested business, and any FDA enforcement could trigger a guidance reset. Diversification into non-GLP-1 specialties is not yet proven at scale, making the stock reliant on regulatory outcomes rather than organic growth resilience. Monitoring Q1 2026 results for evidence of demand recovery from shipping cadence headwinds is critical, as weakness could signal deeper issues. Ultimately, this development shifts the catalyst path slightly but does not alter the fundamental need for caution until regulatory clarity emerges.

Thesis delta

The DeepValue thesis centered on a 6–9 month catalyst path from FDA and Novo Nordisk actions threatening compounded semaglutide access; the reported partnership directly addresses the litigation component, reducing that specific risk. However, the FDA's regulatory intent remains unchanged, so the thesis now hinges more heavily on potential API supply restrictions and marketing constraints, with the bull case requiring HIMS to navigate these while diversifying. Investors should adjust their risk assessment to reflect a partially mitigated litigation threat but an unchanged high-stakes regulatory environment that could still break the guidance assumption.